Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Stock Information for Clene Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Clene Inc.

Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
Clene Announces $7 Million Underwritten Offering of Common Stock
Clene to Present at Upcoming May Conferences
Presenting on Emerging Growth Conference 92 Day 1 on May 6; Register to live stream
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts
Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live stream

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.